Your privacy is very important for us. When you visit our website, please agree to use all cookies. For more information about how we use cookies, please visit our Privacy Policy.

中

News Center

6756758(2)-91.jpg

LaNova Medicines Completes USD 42 Million Series C1 Financing to Accelerate Clinical Progress and Innovation Platform Development

Learn More

All

2025

2024

2023

2022

2021

2020

CDE Granted LM-108 Breakthrough Therapy Designation for 2L CCR8-Positive G/GEJ Adenocarcinomas

2025-06-26

Learn More
LaNova Medicines Announces IND Approval of LM-168 by NMPA

2025-06-11

Learn More
LaNova Medicines Announces FDA Clearance of the IND Application for a Phase 2 study of LM-108 in Combination with other Anti-Cancer Agents

2025-04-16

Learn More
LaNova Medicines Announces FDA Clearance of the IND Application for a Phase 2 study of LM-302 in Combination with Anti-PD-1 Antibody

2025-03-27

Learn More
CDE Granted LM-108 Breakthrough Therapy Designation for MSI-H/dMMR Solid Tumors

2025-02-08

Learn More
LaNova Medicines Announces IND Approval of LM-168 by US FDA

2025-01-16

Learn More

1